Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer

Next Previous
Trial Profile

A Randomized, Open-Label Study to Assess the Pain, Toxicity, and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated With Chemoradiation for Head and Neck Cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gabapentin (Primary) ; Methadone (Primary) ; Oxycodone (Primary) ; Venlafaxine (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use

Most Recent Events

  • 08 Dec 2021 Status changed from active, no longer recruiting to completed.
  • 11 Mar 2021 Planned End Date changed from 1 Mar 2022 to 21 Apr 2022.
  • 11 Mar 2021 Planned primary completion date changed from 1 Mar 2021 to 21 Apr 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top